The Safety of Four Different Dose Levels of Wobenzym in HIV-Positive Patients

Mucos Pharma GmbH and Co

Overview

To study the safety and efficacy of four different doses of Wobenzym (an enzyme combination consisting of pancreatin, papain, bromelain, trypsin, lipase, amylase, chymotrypsin, and rutin) in patients with HIV infection whose CD4 count is between 250 and 400 cells/mm3. To evaluate the effect of Wobenzym on certain surrogate markers associated with progression of HIV disease.

Study Type

INTERVENTIONAL

Purpose

TREATMENT

Conditions

HIV Infections

Interventions

WobenzymDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria Patients must have: HIV seropositivity with CD4 counts between 250 and 400 cells/mm3. Exclusion Criteria Co-existing Condition: Patients with the following symptoms or conditions are excluded: * Known hypersensitivity to hydrolytic enzymes such as Wobenzym. * Known sensitivity to lactose. * Presumption that the patient will not comply with the dosing schedule or follow-up appointments. Concurrent Medication: Excluded: * Concurrent use of immunosuppressive therapy or steroids.

Locations (1)

Saint Luke's - Roosevelt Hosp Ctr

New York, New York, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.